<?xml version="1.0" encoding="UTF-8"?>
<search_results count="1046">
  <query>SEARCH[STUDY] ( Crohn's Disease [STUDY:ALL-FIELDS] )</query>
  <clinical_study>
    <order>201</order>
    <score>0.92428</score>
    <nct_id>NCT02580617</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02580617</url>
    <title>A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: ALLO-ASC</intervention_summary>
    <last_changed>October 19, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>202</order>
    <score>0.92394</score>
    <nct_id>NCT00267722</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00267722</url>
    <title>Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Visilizumab</intervention_summary>
    <last_changed>March 6, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>203</order>
    <score>0.92381</score>
    <nct_id>NCT00899678</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00899678</url>
    <title>The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Certolizumab Pegol; Drug: Certolizumab Pegol</intervention_summary>
    <last_changed>March 3, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>204</order>
    <score>0.92376</score>
    <nct_id>NCT02450513</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02450513</url>
    <title>Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Adalimumab</intervention_summary>
    <last_changed>May 23, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>205</order>
    <score>0.92368</score>
    <nct_id>NCT01696942</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01696942</url>
    <title>Cimzia Versus Mesalamine for Crohn's Recurrence</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Cimzia; Drug: Mesalamine</intervention_summary>
    <last_changed>July 8, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>206</order>
    <score>0.92331</score>
    <nct_id>NCT01559142</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01559142</url>
    <title>Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Infliximab with azathioprine (IIFX + AZA); Drug: Infliximab (IFX alone)</intervention_summary>
    <last_changed>April 2, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>207</order>
    <score>0.92314</score>
    <nct_id>NCT01536418</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01536418</url>
    <title>An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GSK1605786A; Drug: GSK1605786A</intervention_summary>
    <last_changed>April 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>208</order>
    <score>0.92306</score>
    <nct_id>NCT00844285</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00844285</url>
    <title>SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Cimzia</intervention_summary>
    <last_changed>July 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>209</order>
    <score>0.92281</score>
    <nct_id>NCT00482092</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00482092</url>
    <title>Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: adult human mesenchymal stem cells; Drug: Placebo</intervention_summary>
    <last_changed>October 27, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>210</order>
    <score>0.92266</score>
    <nct_id>NCT02685683</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02685683</url>
    <title>Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GED-0301</intervention_summary>
    <last_changed>June 28, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>211</order>
    <score>0.92256</score>
    <nct_id>NCT00492791</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00492791</url>
    <title>Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: wireless endoscopy capsule</intervention_summary>
    <last_changed>April 16, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>212</order>
    <score>0.92253</score>
    <nct_id>NCT03064815</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03064815</url>
    <title>The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies</title>
    <status open="N">Completed</status>
    <condition_summary>Spondyloarthropathy; Crohn Disease</condition_summary>
    <intervention_summary>Device: Videocapsule endoscopy; Procedure: colonoscopy; Diagnostic Test: PROMETHEUS® IBD sgi Diagnostic™; Diagnostic Test: Fecal calprotectin</intervention_summary>
    <last_changed>February 27, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>213</order>
    <score>0.92239</score>
    <nct_id>NCT00267709</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00267709</url>
    <title>Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Visilizumab</intervention_summary>
    <last_changed>March 6, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>214</order>
    <score>0.92189</score>
    <nct_id>NCT01635543</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01635543</url>
    <title>Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease; Peri-anal Fistulas; Sexual Dysfunction</condition_summary>
    <last_changed>October 16, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>215</order>
    <score>0.92164</score>
    <nct_id>NCT00152490</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00152490</url>
    <title>A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Certolizumab Pegol (CDP870)</intervention_summary>
    <last_changed>September 6, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>216</order>
    <score>0.92136</score>
    <nct_id>NCT00406653</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00406653</url>
    <title>A Study of Abatacept in Patients With Active Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: abatacept; Drug: placebo; Drug: abatacept</intervention_summary>
    <last_changed>September 10, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>217</order>
    <score>0.9211</score>
    <nct_id>NCT03108326</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03108326</url>
    <title>Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Biological: Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra</intervention_summary>
    <last_changed>April 5, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>218</order>
    <score>0.92105</score>
    <nct_id>NCT00561548</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00561548</url>
    <title>Impact of Anti-Tumor Necrosis Factor (TNF) Antibodies on the T-lymphocyte and Macrophage Cooperation in Crohn Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Procedure: rectosigmoïdal biopsies</intervention_summary>
    <last_changed>May 27, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>219</order>
    <score>0.92101</score>
    <nct_id>NCT02826330</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02826330</url>
    <title>Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Genetic Predisposition</condition_summary>
    <intervention_summary>Other: biomarkers</intervention_summary>
    <last_changed>July 4, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>220</order>
    <score>0.9207</score>
    <nct_id>NCT00571337</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00571337</url>
    <title>Stop Infliximab in Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Infliximab</intervention_summary>
    <last_changed>July 22, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>221</order>
    <score>0.9207</score>
    <nct_id>NCT01817972</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01817972</url>
    <title>Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Certolizumab pegol; Drug: Azathioprine</intervention_summary>
    <last_changed>March 21, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>222</order>
    <score>0.92054</score>
    <nct_id>NCT01183845</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01183845</url>
    <title>Evaluation of the Applicability of the CDEIS to Data Obtained by the Colonic Capsule Endoscopy in Crohn Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Procedure: Colon Capsule Endoscopy</intervention_summary>
    <last_changed>April 26, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>223</order>
    <score>0.92016</score>
    <nct_id>NCT01915927</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01915927</url>
    <title>Stem Cell Fistula Plug in Perianal Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Perianal Crohn's Disease</condition_summary>
    <intervention_summary>Drug: MSC-AFP</intervention_summary>
    <last_changed>July 3, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>224</order>
    <score>0.91957</score>
    <nct_id>NCT02255370</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02255370</url>
    <title>Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Curcumin</intervention_summary>
    <last_changed>July 25, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>225</order>
    <score>0.91955</score>
    <nct_id>NCT02914600</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02914600</url>
    <title>Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Filgotinib; Drug: Placebo</intervention_summary>
    <last_changed>July 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>226</order>
    <score>0.91938</score>
    <nct_id>NCT03017014</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03017014</url>
    <title>A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>August 2, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>227</order>
    <score>0.91909</score>
    <nct_id>NCT02968108</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02968108</url>
    <title>A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Ustekinumab</intervention_summary>
    <last_changed>July 11, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>228</order>
    <score>0.91894</score>
    <nct_id>NCT00040521</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00040521</url>
    <title>Study Evaluating rhIL-11 in Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Drug: Recombinant Human Interleukin-11 (rhIL-11)</intervention_summary>
    <last_changed>February 7, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>229</order>
    <score>0.91894</score>
    <nct_id>NCT01233960</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01233960</url>
    <title>Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: adult human mesenchymal stem cells</intervention_summary>
    <last_changed>October 27, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>230</order>
    <score>0.91861</score>
    <nct_id>NCT01826188</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01826188</url>
    <title>Combined THC and CBD Drops for Treatment of Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: THC 5 mg/ml and CBD 50 mg/ml.</intervention_summary>
    <last_changed>February 23, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>231</order>
    <score>0.9185</score>
    <nct_id>NCT00554710</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00554710</url>
    <title>Top Down Versus Step Up Strategies in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: infliximab+azathioprine; Drug: methylprednisolone or budesonide</intervention_summary>
    <last_changed>November 6, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>232</order>
    <score>0.91846</score>
    <nct_id>NCT00513552</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00513552</url>
    <title>Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Rifabutin, Clarithromycin, and Clofazimine</intervention_summary>
    <last_changed>August 7, 2007</last_changed>
  </clinical_study>
  <clinical_study>
    <order>233</order>
    <score>0.91844</score>
    <nct_id>NCT02867540</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02867540</url>
    <title>Comparison of Endoscopy and Diffusion-weighted Enterography-MRI for the Diagnosis of Crohn's Disease Recurrence Following Ileocolic Resection: a Pilot Study</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: MRI enterography</intervention_summary>
    <last_changed>August 11, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>234</order>
    <score>0.91788</score>
    <nct_id>NCT01094613</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01094613</url>
    <title>Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Delayed Release 6 mercaptopurine; Drug: 6 Mercaptopurine</intervention_summary>
    <last_changed>March 6, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>235</order>
    <score>0.91784</score>
    <nct_id>NCT02716454</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02716454</url>
    <title>Early Surgery Versus Conservative Treatment in Patients With Ileocaecal Crohn's Disease</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Procedure: Ileocaecal resection</intervention_summary>
    <last_changed>April 26, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>236</order>
    <score>0.9177</score>
    <nct_id>NCT01438151</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01438151</url>
    <title>Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Remicade</intervention_summary>
    <last_changed>March 4, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>237</order>
    <score>0.91766</score>
    <nct_id>NCT01086553</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01086553</url>
    <title>9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn´s Disease</condition_summary>
    <intervention_summary>Drug: budesonide; Drug: budesonide</intervention_summary>
    <last_changed>October 29, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>238</order>
    <score>0.91737</score>
    <nct_id>NCT01181765</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01181765</url>
    <title>The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Infliximab 5 mg/kg body weight infused over 2 hours</intervention_summary>
    <last_changed>December 13, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>239</order>
    <score>0.91736</score>
    <nct_id>NCT01287897</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01287897</url>
    <title>A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection</intervention_summary>
    <last_changed>December 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>240</order>
    <score>0.91723</score>
    <nct_id>NCT00333788</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00333788</url>
    <title>Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Certolizumab pegol (CDP870)</intervention_summary>
    <last_changed>August 30, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>241</order>
    <score>0.91708</score>
    <nct_id>NCT01635621</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01635621</url>
    <title>A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Olokizumab (OKZ); Drug: Placebo</intervention_summary>
    <last_changed>October 29, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>242</order>
    <score>0.91697</score>
    <nct_id>NCT00349752</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00349752</url>
    <title>Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: certolizumab pegol 400 mg; Other: Placebo</intervention_summary>
    <last_changed>August 26, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>243</order>
    <score>0.91691</score>
    <nct_id>NCT00417690</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00417690</url>
    <title>High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: 4-Aminosalicylic acid; Drug: PASER placebo granules</intervention_summary>
    <last_changed>October 14, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>244</order>
    <score>0.91686</score>
    <nct_id>NCT01009281</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01009281</url>
    <title>An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Drug: AIN457</intervention_summary>
    <last_changed>May 31, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>245</order>
    <score>0.91671</score>
    <nct_id>NCT01288053</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01288053</url>
    <title>Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: Allogeneic Stem Cell Therapy</intervention_summary>
    <last_changed>July 11, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>246</order>
    <score>0.91667</score>
    <nct_id>NCT01697761</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01697761</url>
    <title>Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; CAM</condition_summary>
    <intervention_summary>Other: Treatment Group; Other: Control Group</intervention_summary>
    <last_changed>November 19, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>247</order>
    <score>0.91632</score>
    <nct_id>NCT00343642</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00343642</url>
    <title>Dietary Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Time and attention + fructo-oligosaccharide placebo; Dietary Supplement: dietary therapy + fructo-oligosaccharide placebo; Drug: Time and attention + active fructooligosaccharide supplementation</intervention_summary>
    <last_changed>January 24, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>248</order>
    <score>0.9161</score>
    <nct_id>NCT00524537</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00524537</url>
    <title>A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>January 20, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>249</order>
    <score>0.91602</score>
    <nct_id>NCT00688636</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00688636</url>
    <title>Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: infliximab; Drug: placebo</intervention_summary>
    <last_changed>September 9, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>250</order>
    <score>0.91592</score>
    <nct_id>NCT00175292</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00175292</url>
    <title>A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease; Inflammatory Bowel Disease</condition_summary>
    <intervention_summary>Drug: Probiotic - VSL#3</intervention_summary>
    <last_changed>May 12, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>251</order>
    <score>0.91551</score>
    <nct_id>NCT02208310</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02208310</url>
    <title>Trial of High Dose Vitamin D in Patient's With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease; Vitamin D Deficiency</condition_summary>
    <intervention_summary>Drug: Cholecalciferol 10,000 IU; Drug: Cholecalciferol 400 IU</intervention_summary>
    <last_changed>July 21, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>252</order>
    <score>0.91518</score>
    <nct_id>NCT02304666</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02304666</url>
    <title>Study of Inflammatory Markers (VNN1) in Crohn Disease and Ulcerative Colitis.</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)</condition_summary>
    <intervention_summary>Procedure: Colonoscopy for biopsies samples</intervention_summary>
    <last_changed>August 28, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>253</order>
    <score>0.91452</score>
    <nct_id>NCT00886327</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00886327</url>
    <title>Detecting Postoperative Recurrence in Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Procedure: Colonic capsule endoscopy</intervention_summary>
    <last_changed>May 30, 2012</last_changed>
  </clinical_study>
  <clinical_study>
    <order>254</order>
    <score>0.91449</score>
    <nct_id>NCT01957423</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01957423</url>
    <title>Immune Response Regulation and Nutritional Status of the Crohn's Disease Patients.</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: Whey protein; Dietary Supplement: Soy protein</intervention_summary>
    <last_changed>September 30, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>255</order>
    <score>0.91432</score>
    <nct_id>NCT01596894</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01596894</url>
    <title>Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Azithromycin + Metronidazole; Drug: Metronidazole</intervention_summary>
    <last_changed>December 6, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>256</order>
    <score>0.9138</score>
    <nct_id>NCT00808262</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00808262</url>
    <title>Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Biological: TNFa Kinoid</intervention_summary>
    <last_changed>June 7, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>257</order>
    <score>0.91373</score>
    <nct_id>NCT02405442</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02405442</url>
    <title>Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: GS-5745; Drug: Placebo</intervention_summary>
    <last_changed>February 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>258</order>
    <score>0.91334</score>
    <nct_id>NCT00353756</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00353756</url>
    <title>Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: C326, IL-6 Inhibitory Avimer protein</intervention_summary>
    <last_changed>October 10, 2006</last_changed>
  </clinical_study>
  <clinical_study>
    <order>259</order>
    <score>0.91323</score>
    <nct_id>NCT01051622</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01051622</url>
    <title>PBMC (Peripheral Blood Mononuclear Cells) /Lymphocyte SPECT (Single Photon Emission Computerized Tomography) Imaging in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Labeling Ceretec</intervention_summary>
    <last_changed>May 29, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>260</order>
    <score>0.91298</score>
    <nct_id>NCT00265772</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00265772</url>
    <title>Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease; Pediatric</condition_summary>
    <intervention_summary>Drug: MODULEN IBD (R) (specific Enteral Nutrition); Drug: prednisolon</intervention_summary>
    <last_changed>December 14, 2005</last_changed>
  </clinical_study>
  <clinical_study>
    <order>261</order>
    <score>0.91296</score>
    <nct_id>NCT01663142</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01663142</url>
    <title>Early Postoperative Recurrence in Crohn's Disease: Predictors of Research Targeting the Constitutional Mutation of IRGM</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Flammatory Bowel Disease; Crohn's Disease</condition_summary>
    <last_changed>October 30, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>262</order>
    <score>0.91284</score>
    <nct_id>NCT02770495</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02770495</url>
    <title>Postoperative REcurrence and DynamICs of T Cell Subsets in Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Other: blood sample</intervention_summary>
    <last_changed>May 10, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>263</order>
    <score>0.91273</score>
    <nct_id>NCT00553176</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00553176</url>
    <title>The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: No intervention</intervention_summary>
    <last_changed>March 1, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>264</order>
    <score>0.91211</score>
    <nct_id>NCT00731809</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00731809</url>
    <title>Evaluation of PET CT in the Management of Patients With Crohn's Disease.</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Radiation: FDG PET CT</intervention_summary>
    <last_changed>December 22, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>265</order>
    <score>0.91192</score>
    <nct_id>NCT02883296</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02883296</url>
    <title>Long-term Follow-up of Anal Fistulae in Crohn's Disease Treated With Anti-TNFalpha and Interest of New MRI Sequences</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Anal Fistula; Crohn's Disease</condition_summary>
    <intervention_summary>Other: Pelvis Magnetic resonance imaging</intervention_summary>
    <last_changed>August 25, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>266</order>
    <score>0.91181</score>
    <nct_id>NCT01820247</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01820247</url>
    <title>Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: enteral nutrition; Drug: Tripterygium glycosides</intervention_summary>
    <last_changed>March 27, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>267</order>
    <score>0.9118</score>
    <nct_id>NCT00275418</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00275418</url>
    <title>Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: beta carotene from Dunaliella algae</intervention_summary>
    <last_changed>January 10, 2006</last_changed>
  </clinical_study>
  <clinical_study>
    <order>268</order>
    <score>0.91159</score>
    <nct_id>NCT02517684</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02517684</url>
    <title>Top-down Infliximab Study in Kids With Crohn's Disease</title>
    <status open="N">Enrolling by invitation</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Infliximab; Drug: Prednisolone; Other: Exclusive enteral nutrition; Drug: Azathioprine</intervention_summary>
    <last_changed>February 8, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>269</order>
    <score>0.91145</score>
    <nct_id>NCT01233570</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01233570</url>
    <title>Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Tacrolimus</intervention_summary>
    <last_changed>November 2, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>270</order>
    <score>0.91113</score>
    <nct_id>NCT02549976</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02549976</url>
    <title>Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Procedure: Abdominal MRI; Procedure: Upper endoscopy; Procedure: Colonoscopy; Procedure: Pelvic MRI</intervention_summary>
    <last_changed>September 14, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>271</order>
    <score>0.91066</score>
    <nct_id>NCT00297193</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00297193</url>
    <title>ASTIC Autologous Stem Cell Transplantation for Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Procedure: Autologous haematopoietic stem cell transplant</intervention_summary>
    <last_changed>August 29, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>272</order>
    <score>0.91037</score>
    <nct_id>NCT02624414</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02624414</url>
    <title>Capsule Colonoscopy in Crohn's Disease and Its Correlation With Conventional Colonoscopy and Faecal Calprotectin</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: PillCam® COLON 2 Capsule Endoscopy</intervention_summary>
    <last_changed>April 12, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>273</order>
    <score>0.9103</score>
    <nct_id>NCT01751152</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01751152</url>
    <title>A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammation; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: NNC0114-0006; Drug: placebo</intervention_summary>
    <last_changed>March 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>274</order>
    <score>0.91006</score>
    <nct_id>NCT00976690</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00976690</url>
    <title>Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Azathioprine OR Mesalazine</intervention_summary>
    <last_changed>August 30, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>275</order>
    <score>0.90988</score>
    <nct_id>NCT02423460</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02423460</url>
    <title>Threonine Requirement in IBD Adults and Healthy Adult Controls</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease; Healthy</condition_summary>
    <intervention_summary>Other: Threonine</intervention_summary>
    <last_changed>September 8, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>276</order>
    <score>0.90985</score>
    <nct_id>NCT02039063</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02039063</url>
    <title>A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease</title>
    <status open="N">Active, not recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: E6011 2 mg/kg; Drug: E6011 5 mg/kg; Drug: E6011 10 mg/kg; Drug: E6011 15 mg/kg</intervention_summary>
    <last_changed>June 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>277</order>
    <score>0.90985</score>
    <nct_id>NCT00025805</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00025805</url>
    <title>G-CSF to Treat Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: G-CSF</intervention_summary>
    <last_changed>June 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>278</order>
    <score>0.90969</score>
    <nct_id>NCT00552058</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00552058</url>
    <title>Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Biological: certolizumab pegol (CDP870, CZP); Other: Placebo</intervention_summary>
    <last_changed>October 14, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>279</order>
    <score>0.90962</score>
    <nct_id>NCT01951326</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01951326</url>
    <title>Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: RHB-104; Drug: Placebo</intervention_summary>
    <last_changed>August 1, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>280</order>
    <score>0.90952</score>
    <nct_id>NCT02240108</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02240108</url>
    <title>One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Rifaximin DR; Drug: Placebo</intervention_summary>
    <last_changed>April 26, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>281</order>
    <score>0.90938</score>
    <nct_id>NCT01297907</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01297907</url>
    <title>Bronchial Hyperreactivity in Children With Crohn Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Methacholine Challenge Test; Other: Fractional Exhaled NO (FENO); Other: Blood Test; Other: PCDAI</intervention_summary>
    <last_changed>February 16, 2011</last_changed>
  </clinical_study>
  <clinical_study>
    <order>282</order>
    <score>0.90936</score>
    <nct_id>NCT01647412</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01647412</url>
    <title>Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease</title>
    <status open="N">Withdrawn</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Growth Hormone; Dietary Supplement: Nutraceutical Combination; Other: Exclusion Diet; Other: Placebo Growth Hormone</intervention_summary>
    <last_changed>April 9, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>283</order>
    <score>0.90933</score>
    <nct_id>NCT00206674</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00206674</url>
    <title>Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Sargramostim (Leukine); Drug: Placebo</intervention_summary>
    <last_changed>December 2, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>284</order>
    <score>0.90925</score>
    <nct_id>NCT01015391</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01015391</url>
    <title>Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: T2; Drug: Azathioprine</intervention_summary>
    <last_changed>June 1, 2013</last_changed>
  </clinical_study>
  <clinical_study>
    <order>285</order>
    <score>0.9092</score>
    <nct_id>NCT02240121</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02240121</url>
    <title>One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Rifaximin DR; Drug: Placebo</intervention_summary>
    <last_changed>April 26, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>286</order>
    <score>0.90899</score>
    <nct_id>NCT01203631</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01203631</url>
    <title>Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Inflammation; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: NNC 0142-0000-0002; Drug: Placebo</intervention_summary>
    <last_changed>July 29, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>287</order>
    <score>0.90859</score>
    <nct_id>NCT03221166</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03221166</url>
    <title>Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors</title>
    <status open="Y">Not yet recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Thalidomide; Drug: Infliximab</intervention_summary>
    <last_changed>July 14, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>288</order>
    <score>0.90843</score>
    <nct_id>NCT02056418</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02056418</url>
    <title>Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Dietary Supplement: enteral nutrition; Drug: corticosteroid</intervention_summary>
    <last_changed>February 4, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>289</order>
    <score>0.90841</score>
    <nct_id>NCT02044952</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02044952</url>
    <title>Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission</title>
    <status open="N">Unknown status</status>
    <condition_summary>Inflammatory Bowel Diseases; Crohn's Disease; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases</condition_summary>
    <intervention_summary>Drug: Mesalazine, Tripterygium glycosides</intervention_summary>
    <last_changed>January 22, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>290</order>
    <score>0.9083</score>
    <nct_id>NCT03138655</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT03138655</url>
    <title>Vedolizumab IV in Pediatric Participants With Ulcerative Colitis or Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Ulcerative Colitis; Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Vedolizumab</intervention_summary>
    <last_changed>June 30, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>291</order>
    <score>0.90822</score>
    <nct_id>NCT01144156</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01144156</url>
    <title>Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy</title>
    <status open="N">Unknown status</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Treatment with Adalimumab</intervention_summary>
    <last_changed>June 14, 2010</last_changed>
  </clinical_study>
  <clinical_study>
    <order>292</order>
    <score>0.90806</score>
    <nct_id>NCT02394028</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02394028</url>
    <title>A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn Disease</condition_summary>
    <intervention_summary>Drug: Etrolizumab 210 mg; Drug: Etrolizumab 105 mg; Drug: Placebo</intervention_summary>
    <last_changed>March 9, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>293</order>
    <score>0.90793</score>
    <nct_id>NCT02769494</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02769494</url>
    <title>The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease; Oral Ulcer</condition_summary>
    <intervention_summary>Drug: Mesalazine Sustained-Release Tablets; Drug: Riboflavin Sodium Phosphate Injection</intervention_summary>
    <last_changed>May 10, 2016</last_changed>
  </clinical_study>
  <clinical_study>
    <order>294</order>
    <score>0.90783</score>
    <nct_id>NCT02704728</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT02704728</url>
    <title>Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Other: Thetanix; Other: Placebo</intervention_summary>
    <last_changed>June 26, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>295</order>
    <score>0.9074</score>
    <nct_id>NCT00007163</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00007163</url>
    <title>Monoclonal Antibody Treatment of Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: J695</intervention_summary>
    <last_changed>March 3, 2008</last_changed>
  </clinical_study>
  <clinical_study>
    <order>296</order>
    <score>0.90737</score>
    <nct_id>NCT01569503</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01569503</url>
    <title>Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease</title>
    <status open="Y">Recruiting</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Device: vagus nerve stimulation (VNS)</intervention_summary>
    <last_changed>February 23, 2017</last_changed>
  </clinical_study>
  <clinical_study>
    <order>297</order>
    <score>0.90727</score>
    <nct_id>NCT00944736</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00944736</url>
    <title>Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Dietary Supplement: VSL#3; Dietary Supplement: Placebo</intervention_summary>
    <last_changed>March 6, 2014</last_changed>
  </clinical_study>
  <clinical_study>
    <order>298</order>
    <score>0.90724</score>
    <nct_id>NCT01564823</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01564823</url>
    <title>Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn´s Disease</condition_summary>
    <intervention_summary>Drug: Metronidazole; Drug: Metronidazole; Drug: Azathioprine; Drug: Adalimumab</intervention_summary>
    <last_changed>March 15, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>299</order>
    <score>0.90723</score>
    <nct_id>NCT01759017</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT01759017</url>
    <title>PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease</title>
    <status open="N">Terminated</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <last_changed>July 20, 2015</last_changed>
  </clinical_study>
  <clinical_study>
    <order>300</order>
    <score>0.90719</score>
    <nct_id>NCT00269386</nct_id>
    <url>https://ClinicalTrials.gov/show/NCT00269386</url>
    <title>Clarithromycin in Active Crohn's Disease</title>
    <status open="N">Completed</status>
    <condition_summary>Crohn's Disease</condition_summary>
    <intervention_summary>Drug: Clarithromycin; Drug: Placebo</intervention_summary>
    <last_changed>January 6, 2009</last_changed>
  </clinical_study>
</search_results>
